Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$734M |
| 2 |
Adobe
ADBE
|
+$488M |
| 3 |
Merck
MRK
|
+$443M |
| 4 |
Tesla
TSLA
|
+$366M |
| 5 |
AGN
Allergan plc
AGN
|
+$315M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$682M |
| 2 |
Perrigo
PRGO
|
+$585M |
| 3 |
Gilead Sciences
GILD
|
+$556M |
| 4 |
EMC
EMC CORPORATION
EMC
|
+$432M |
| 5 |
Morgan Stanley
MS
|
+$401M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.94% |
| 2 | Consumer Discretionary | 14.99% |
| 3 | Communication Services | 11.27% |
| 4 | Technology | 9.94% |
| 5 | Financials | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Texas Roadhouse
TXRH
$13.7B
| $34.9M | 0.03% |
1,256,529
-102,249
| -8% | -$2.78M |
|
|
MACK
377
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $34.9M | 0.03% |
830,809
+137,939
| +20% | +$4M |
|
|
HT
378
DELISTED
Hersha Hospitality Trust Priority Class A Common Shares of Beneficial Interest
HT
| $34.9M | 0.03% |
1,566,277
-114,641
| -7% | -$2.6M |
|
|
TMH
379
DELISTED
Team Health Holdings Inc
TMH
| $34.3M | 0.03% |
752,565
-47,979
| -6% | -$2.13M |
|
|
STJ
380
DELISTED
St Jude Medical
STJ
| $34.2M | 0.03% |
+552,343
| New | +$32M |
|
|
SODA
381
DELISTED
SodaStream International Ltd
SODA
| $33.7M | 0.03% |
+678,308
| New | +$38.6M |
|
|
EMC
382
DELISTED
EMC CORPORATION
EMC
| $33.3M | 0.03% |
1,323,486
-17,819,528
| -93% | -$432M |
|
383
Travelers Companies
TRV
$81.1B
| $33.2M | 0.03% |
366,544
-7,092
| -2% | -$620K |
|
|
INXN
384
DELISTED
Interxion Holding N.V.
INXN
| $33.2M | 0.03% |
1,404,990
+475,857
| +51% | +$10.8M |
|
|
SCHW
385
Charles Schwab
SCHW
$182B
| $32.9M | 0.03% |
1,264,610
-5,249
| -0.4% | -$125K |
|
386
Kinross Gold
KGC
$27.7B
| $32.3M | 0.03% |
7,382,523
-12,732,364
| -63% | -$60.7M |
|
387
Toyota
TM
$228B
| $32.3M | 0.03% |
265,093
-51,007
| -16% | -$6.41M |
|
388
Brink's
BCO
$5.01B
| $31.8M | 0.03% |
931,866
+8,898
| +1% | +$280K |
|
389
Antero Resources
AR
$10.9B
| $31.8M | 0.03% |
+500,930
| New | +$28M |
|
|
DBD
390
DELISTED
Diebold Nixdorf Incorporated
DBD
| $31.7M | 0.03% |
959,923
+20,365
| +2% | +$635K |
|
|
YHOO
391
DELISTED
Yahoo Inc
YHOO
| $31.5M | 0.03% |
778,267
-419,153
| -35% | -$15M |
|
|
JNPR
392
DELISTED
Juniper Networks
JNPR
| $31.3M | 0.03% |
1,388,526
-2,867
| -0.2% | -$58.1K |
|
|
TWTC
393
DELISTED
TW TELECOM INC CL A COM
TWTC
| $30.8M | 0.03% |
1,012,449
-304,964
| -23% | -$9.1M |
|
|
PPL
394
PPL Corp
PPL
$26.9B
| $30.7M | 0.03% |
1,097,168
| – | – |
|
|
BCA
395
DELISTED
CORPBANCA SPONSORED ADR REPSTG (1-1,500)COM STK
BCA
| $30.4M | 0.03% |
1,439,268
| – | – |
|
396
Edison International
EIX
$30.3B
| $30.4M | 0.03% |
656,907
| – | – |
|
|
LMOS
397
DELISTED
Lumos Networks Corp
LMOS
| $30.4M | 0.03% |
1,445,813
+128,507
| +10% | +$2.84M |
|
398
Wheaton Precious Metals
WPM
$49.7B
| $30.1M | 0.03% |
1,489,921
-28,922
| -2% | -$628K |
|
|
WX
399
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
| $30M | 0.03% |
782,943
+8,380
| +1% | +$265K |
|
|
I
400
DELISTED
INTELSAT S. A.
I
| $29.7M | 0.03% |
1,317,670
+477
| +0% | +$10.3K |
|
Similar funds
Jennison Associates's Q4 2013 Portfolio in Review
As of Q4 2013, Jennison Associates held 759 positions worth $102B, up 6.9% from $95.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates's Q4 2013 filing shows 79 new, 184 increased, 411 reduced and 54 closed positions. Its largest new stake was Allergan plc: 2,016,619 shares worth $339M. The largest sale was UnitedHealth, an estimated $682M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q4 2013 buy was Allergan plc: 2,016,619 shares worth $339M.
- Jennison Associates added most to Bristol-Myers Squibb in Q4 2013, an estimated $734M increase.
- Jennison Associates's biggest Q4 2013 reduction was UnitedHealth, cutting an estimated $682M.
- Jennison Associates fully exited Perrigo in Q4 2013, selling an estimated $585M.
- Jennison Associates's ten largest holdings make up 20% of its $102B portfolio in Q4 2013.
- Jennison Associates opened 79 new positions and closed 54 in Q4 2013.
- Jennison Associates's portfolio value rose 6.9% quarter-over-quarter to $102B.
Based on Jennison Associates's 13F filing for Q4 2013, filed 10 Feb 2014.